Header Logo

Connection

JORGE CASTILLO to Lymphoma, Large B-Cell, Diffuse

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Lymphoma, Large B-Cell, Diffuse.
JORGE CASTILLO
Connection Strength
12.884
Lymphoma, Large B-Cell, Diffuse
  1. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024 Oct; 99(10):2002-2015.
    View in: PubMed
    Score: 0.800
  2. Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. JCO Glob Oncol. 2022 11; 8:e2200165.
    View in: PubMed
    Score: 0.712
  3. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022 07; 97(7):951-965.
    View in: PubMed
    Score: 0.688
  4. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK?+?LBCL): a systematic review of clinicopathological features and management. Leuk Lymphoma. 2021 12; 62(12):2845-2853.
    View in: PubMed
    Score: 0.648
  5. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 04; 95(4):435-445.
    View in: PubMed
    Score: 0.592
  6. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 07; 93(7):953-962.
    View in: PubMed
    Score: 0.527
  7. Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. J Natl Compr Canc Netw. 2016 09; 14(9):1121-9.
    View in: PubMed
    Score: 0.465
  8. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr?m macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
    View in: PubMed
    Score: 0.461
  9. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol. 2016 Aug; 91(8):E324.
    View in: PubMed
    Score: 0.454
  10. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 May; 91(5):529-37.
    View in: PubMed
    Score: 0.454
  11. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug; 26(8):1163-72.
    View in: PubMed
    Score: 0.427
  12. CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis. Am J Hematol. 2015 Mar; 90(3):E49-50.
    View in: PubMed
    Score: 0.419
  13. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol. 2015 Jun; 8(3):343-54.
    View in: PubMed
    Score: 0.416
  14. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 09; 125(15):2323-30.
    View in: PubMed
    Score: 0.416
  15. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015 May; 169(3):352-5.
    View in: PubMed
    Score: 0.416
  16. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res. 2014 Aug; 38(8):866-73.
    View in: PubMed
    Score: 0.395
  17. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014 Mar; 89(3):310-4.
    View in: PubMed
    Score: 0.390
  18. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):122-30.
    View in: PubMed
    Score: 0.383
  19. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013 Apr; 37(4):386-91.
    View in: PubMed
    Score: 0.362
  20. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012 Apr; 36(4):413-7.
    View in: PubMed
    Score: 0.338
  21. Plasmablastic lymphoma: a systematic review. ScientificWorldJournal. 2011 Mar 22; 11:687-96.
    View in: PubMed
    Score: 0.318
  22. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011; 16(1):87-96.
    View in: PubMed
    Score: 0.314
  23. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010 Nov; 51(11):2047-53.
    View in: PubMed
    Score: 0.308
  24. Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL). J Geriatr Oncol. 2025 01; 16(1):102160.
    View in: PubMed
    Score: 0.206
  25. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
    View in: PubMed
    Score: 0.198
  26. Real-world experience in older patients with diffuse large B-cell lymphoma treated in Latin America: A study by the Latin American study group of lymphoproliferative disorders (GELL). J Geriatr Oncol. 2023 09; 14(7):101565.
    View in: PubMed
    Score: 0.187
  27. Primary cutaneous Epstein-Barr virus-positive B-cell lymphoid proliferation with features of diffuse large B-cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. Int J Dermatol. 2023 02; 62(2):e87-e90.
    View in: PubMed
    Score: 0.169
  28. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leuk Res. 2021 03; 102:106513.
    View in: PubMed
    Score: 0.157
  29. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):637-646.
    View in: PubMed
    Score: 0.150
  30. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12.
    View in: PubMed
    Score: 0.147
  31. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):e551-e557.
    View in: PubMed
    Score: 0.141
  32. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85.
    View in: PubMed
    Score: 0.129
  33. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383.
    View in: PubMed
    Score: 0.125
  34. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018 Feb; 36(1):93-97.
    View in: PubMed
    Score: 0.123
  35. Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus? Cardiovasc Pathol. 2015 Jan-Feb; 24(1):60-4.
    View in: PubMed
    Score: 0.101
  36. EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):512-6.
    View in: PubMed
    Score: 0.082
  37. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011 Aug; 86(8):663-7.
    View in: PubMed
    Score: 0.082
  38. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. Leuk Lymphoma. 2011 Jan; 52(1):153-6.
    View in: PubMed
    Score: 0.078
  39. Management of HIV-associated lymphomas. Med Health R I. 2011 Jan; 94(1):4-6.
    View in: PubMed
    Score: 0.078
  40. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.